Free Trial
NYSE:NHWK

NightHawk Biosciences (NHWK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.26
$0.50
52-Week Range
N/A
Volume
173,100 shs
Average Volume
97,242 shs
Market Capitalization
$10.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NHWK stock logo

About NightHawk Biosciences Stock (NYSE:NHWK)

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

NHWK Stock News Headlines

Scorpius Holdings GAAP EPS of -$1.74
Scorpius Holdings, Inc. (SCPX)
NHWK: Transformational Changes
NightHawk Biosciences Inc NHWK
See More Headlines
Receive NHWK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
6/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
77
Year Founded
2008

Profitability

Net Income
$-43,440,000.00
Net Margins
-2,333.27%
Pretax Margin
-2,546.97%

Debt

Sales & Book Value

Annual Sales
$6.38 million
Book Value
$2.82 per share

Miscellaneous

Free Float
21,935,000
Market Cap
$10.78 million
Optionable
Optionable
Beta
0.19

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Jeffrey Alan Wolf J.D. (Age 61)
    Founder, Chairman of the Board, CEO & President
    Comp: $842.6k
  • Mr. William L. Ostrander (Age 56)
    CFO & Secretary
    Comp: $476.24k
  • Dr. Justin Stebbing FRCP
    FRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr.
    F.A.C.S., M.D., Chief Medical Advisor
  • Ms. Ania Szymanska
    Head of Quality

NHWK Stock Analysis - Frequently Asked Questions

How were NightHawk Biosciences' earnings last quarter?

NightHawk Biosciences, Inc. (NYSE:NHWK) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.57 million. NightHawk Biosciences had a negative net margin of 2,333.27% and a negative trailing twelve-month return on equity of 91.62%.

When did NightHawk Biosciences' stock split?

NightHawk Biosciences shares reverse split on Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

This page (NYSE:NHWK) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners